Raymie McFarland New Monarch Medical Technologies President/CEO: Experienced Industry Executive

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

How To Control a Radio Frequency (RF) Process

The radio frequency welding and manufacturing process uses electromagnetic energy and pressure to fuse and permanently bond vinyl, thermoplastic, and coated materials to produce a specific product - all according to customer requirements. Using this RF sealing process, a distinct, one-piece perpetual bond is formulated that is both solid and resistant to ripping or tearing. But how is this process controlled, and with what specific tools? Read on.

Raymie McFarland will serve as the new President and CEO of Monarch Medical Technologies.

Raymie McFarland has been deeply entrenched in the diabetes technology, consultancy and pharmaceutical sectors of the healthcare industry for more than 20 years. Among thought leaders and colleagues, he is known as much for his subject matter expertise, creativity and resourcefulness as he is for his strategic foresight and charisma.

Brian Duffy and Christophe Mallard, two of Monarch Medical Technologies’ Board members, will relinquish their respective roles as Interim Chief Executive Officer and Interim President, turning over day-to-day management of the company to McFarland. Says Duffy, “We are thrilled to welcome Raymie to the Monarch family. He is, as many people will attest, a one-of-a-kind talent. His in-depth knowledge of diabetes and, more specifically, of glycemic management and insulin therapies, is extraordinary.”

Adds Mallard, “Raymie’s track record of success in cultivating customer relationships, building high-performing teams, engaging key opinion leaders and generating revenue is unimpeachable. He has a keen ability to articulate the benefits of innovative tools, technologies and processes to clinicians, administrators and senior executives alike. He is also highly experienced in conducting scientific research and measuring both clinical efficacy and financial ROI.”

McFarland spent the last nine years with Glytec, most recently as Chief Innovation & Outcomes Officer. During his tenure, McFarland added more than 200 sites to the company’s customer roster, built a Quality Initiatives division from the ground up and directed more than 85 diabetes-related research studies. Prior to Glytec, McFarland was President of Mantra Healthcare Solutions, a glycemic management consultancy he co-founded. Earlier in his career, McFarland worked for pharmaceutical giant, Sanofi, where he developed and facilitated multiple programs aimed at improving the care of persons with diabetes.

McFarland holds certifications from CMS Readmissions Programming, Telehealth Remote Monitoring, Quality Lean Processing, Six Sigma and Quality Institute.

“Although there is no playbook for leadership in the face of a pandemic,” says Duffy, “we have the utmost confidence that Raymie’s strong business acumen and customer-first mindset is exactly what Monarch needs. He is well positioned to address the challenges of our nation’s healthcare providers and persons with diabetes.”



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.